Vaccine Info

Pentacel Vaccine

Pentacel Description

Pentacel vaccine consists of Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus (DTaP-IPV) component and an ActHIB® vaccine component 

Pentacel Indication

Pentacel vaccine is indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis, and invasive disease due to H influenzae type b.

Pentacel Dosage

Pentacel is administered as an intramuscular injection.

Pentacel vaccine is approved for use as a 4-dose series in children 6 weeks through 4 years of age (prior to the fifth birthday).

Pentacel News

June 23, 2008 - Sanofi Pasteur, announced that the U.S. Food and Drug Administration (FDA) has licensed Pentacel® vaccine that is approved for use in infants and children 6 weeks through 4 years of age (prior to the fifth birthday).

Pentacel® vaccine is the first and only four-dose diphtheria, tetanus, and acellular pertussis (DTaP)-based combination vaccine for use in infants and young children in the U.S. that includes both poliovirus and Hib antigens.

Updated
08/18/2020 - 12:21